|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The present amplification via primer ligation at the mutation (APRIL-ATM) has potential applications in the detection of mutagen-generated genetic alterations, early detection of tumor marker mutations in bodily discharges and the diagnosis of minimal residual disease.
|
12202623 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor growth-promoting as well as apoptosis-inducing effects of APRIL have been described.
|
11550092 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, APRIL-transfected NIH-3T3 cells show an increased rate of tumor growth in nude mice compared with the parental cell line.
|
9743536 |
1998 |
|
Rheumatoid Arthritis
|
0.070 |
Biomarker
|
disease |
BEFREE |
The role of BAFF and APRIL in rheumatoid arthritis.
|
30941763 |
2019 |
|
Rheumatoid Arthritis
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
In addition, BAFF and APRIL are involved in the pathogenesis of a number of human autoimmune diseases, with elevated levels of these cytokines detected in the sera of patients with systemic lupus erythematosus (SLE), IgA nephropathy, Sjögren's syndrome, and rheumatoid arthritis.
|
28215100 |
2017 |
|
Rheumatoid Arthritis
|
0.070 |
Biomarker
|
disease |
BEFREE |
APRIL also promoted B10 cells in RA patients.
|
27372914 |
2016 |
|
Rheumatoid Arthritis
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
RASF, rheumatoid arthritis dermal fibroblasts (RADF) and osteoarthritis synovial fibroblasts (OASF) were analysed for the expression of B cell survival/proliferating factors BAFF and APRIL in resting conditions and upon stimulation with TLR2/TLR3/TLR4 ligands.
|
21798884 |
2011 |
|
Rheumatoid Arthritis
|
0.070 |
Biomarker
|
disease |
BEFREE |
Association of APRIL and TWEAK with rheumatoid arthritis (RA) was examined in parallel.
|
17307753 |
2007 |
|
Rheumatoid Arthritis
|
0.070 |
Biomarker
|
disease |
BEFREE |
APRIL stimulated RA FLS, but not OA FLS, to produce IL-6, TNFalpha, IL-1beta, and APRIL itself.
|
17968879 |
2007 |
|
Rheumatoid Arthritis
|
0.070 |
Biomarker
|
disease |
BEFREE |
BLyS and APRIL in rheumatoid arthritis.
|
16239971 |
2005 |
|
Autoimmune Diseases
|
0.060 |
Biomarker
|
group |
BEFREE |
Therefore, Anp32b appears to fulfill a role in regulating adequate adaptive immune responses and, hence, may be involved in dysregulation of pathways leading to autoimmune disorders and/or immune deficiencies.
|
30890743 |
2019 |
|
Multiple Myeloma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma.
|
31698455 |
2019 |
|
Multiple Myeloma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Taken together, these results define novel APRIL actions via TACI on Tregs and Bregs to promote MM cell survival, providing the rationale for targeting APRIL/TACI system to alleviate the immunosuppressive BM milieu and improve patient outcome in MM.
|
30135465 |
2019 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Overall, our results showed that chemokine-mediated recruitment of neutrophils secreting the tumor-promoting factor APRIL mediates DLBCL progression.<i>Cancer Res; 77(5); 1097-107.©2016 AACR</i>.
|
27923834 |
2017 |
|
Multiple Myeloma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Characteristics of BAFF and APRIL factor expression in multiple myeloma and clinical significance.
|
28928810 |
2017 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
APRIL was observed near Ki67(+) nuclei and was distributed heterogeneously in the cancer cells, in the leukocyte infiltrate, and in the myoepithelial layer adjacent to the tumor area; these results imply that APRIL provides proliferation signals to tumor cells through paracrine and autocrine signaling.
|
25750171 |
2015 |
|
Multiple Myeloma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Myelopoiesis dysregulation associated to sustained APRIL production in multiple myeloma-infiltrated bone marrow.
|
25753925 |
2015 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
APRIL can stimulate tumor cell growth and is up-expressed in cancer tissues, especially in CRC (colorectal cancer).
|
24771268 |
2014 |
|
Chronic Lymphocytic Leukemia
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
We further analysed the prognostic value of BAFF and APRIL receptors expression in patients with CLL.
|
24245956 |
2014 |
|
Chronic Lymphocytic Leukemia
|
0.060 |
Biomarker
|
disease |
BEFREE |
These findings indicate that APRIL has an important role in CLL and that the APRIL-TACI interaction might be a selective novel therapeutic target for human CLL.
|
24100449 |
2013 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
APRIL has also been associated with a wide range of solid malignancies, including colorectal cancer (CRC).
|
22705846 |
2012 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Simultaneous knockdown of APRIL via multiple shRNAs reduces the malignancy of SW480 cells.
|
22923013 |
2012 |
|
Autoimmune Diseases
|
0.060 |
Biomarker
|
group |
BEFREE |
The B-cell survival factors APRIL and BLyS are important for B-cell maturation and activation and contribute to human autoimmune diseases.
|
20890272 |
2011 |
|
Multiple Myeloma
|
0.060 |
Biomarker
|
disease |
BEFREE |
It was shown that NFkB activation in MM tumors results mainly from extrinsic signaling by APRIL and BAFF ligands that stimulate receptors on normal plasma cells as well as on pre-malignant monoclonal gammopathy of undetermined significance (MGUS) and MM tumors.
|
20890394 |
2010 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Taken together, these data suggest that APRIL is a potential prognostic factor for a large array of malignancies.
|
19291294 |
2009 |